Read more about their work in @science.org ➡️ https://bit.ly/3Xd4Dgp
Read more about their work in @science.org ➡️ https://bit.ly/3Xd4Dgp
👉 vist.ly/5smy3
#Immunotherapy
👉 vist.ly/5smy3
#Immunotherapy
KEYNOTE-C93 et TroFuse-005 évaluent 2 stratégies : le pembrolizumab en monothérapie en 1ère ligne dMMR et le sacituzumab tirumotecan après traitement. Analyse de Dre Diana Bello Roufai (Institut Curie).
https://mdsc.pe/4Apo5Vw
KEYNOTE-C93 et TroFuse-005 évaluent 2 stratégies : le pembrolizumab en monothérapie en 1ère ligne dMMR et le sacituzumab tirumotecan après traitement. Analyse de Dre Diana Bello Roufai (Institut Curie).
https://mdsc.pe/4Apo5Vw
Sign up to read the full recap ➡️! www.onclive.com/view/gi-canc...
Sign up to read the full recap ➡️! www.onclive.com/view/gi-canc...
by Ghelardi F, Ambrosini M (...) Pietrantonio F et 51 al. in Nat Med #MedSky
👉 get more here
📖 read the article:
https://cancerletter.com/clinical/20261030_3/
https://cancerletter.com/clinical/20261030_3/
Link in the comments 👇
#Atezolizumab #Immunotherapy #Oncology
Link in the comments 👇
#Atezolizumab #Immunotherapy #Oncology
by Cercek A, Bachet JB (...) Roodhart JML et 32 al. in Ann Oncol #MedSky
👉 get more here
📖 read the article: here
->Nature | More on "Neoadjuvant immunotherapy for colon cancer" at BigEarthData.ai
www.annalsofoncology.org/article/S092...
📊 Final CheckMate 8HW results demonstrate:
🔹 OS benefit vs nivolumab across all treatment lines 🔹 OS benefit vs chemotherapy in 1L (HR 0.37)
www.annalsofoncology.org/article/S092...
📊 Final CheckMate 8HW results demonstrate:
🔹 OS benefit vs nivolumab across all treatment lines 🔹 OS benefit vs chemotherapy in 1L (HR 0.37)
https://cancerletter.com/clinical/20261030_3/
https://cancerletter.com/clinical/20261030_3/
See more👇
thepharmanavigator.com/news/gsk-win...
See more👇
thepharmanavigator.com/news/gsk-win...
https://cancerletter.com/clinical/20261030_3/
https://cancerletter.com/clinical/20261030_3/
https://www.medpagetoday.com/meetingcoverage/esmo/123637
https://www.medpagetoday.com/meetingcoverage/esmo/123637
This paper by M. Chalabi, L.D.W. van den Dungen, P.G.M. de Gooyer, ... & J.B.A.G. Haanen has been voted as our Scientific Publication of week 43
www.thelancet.com/journals/lan...
This paper by M. Chalabi, L.D.W. van den Dungen, P.G.M. de Gooyer, ... & J.B.A.G. Haanen has been voted as our Scientific Publication of week 43
www.thelancet.com/journals/lan...